Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating novel vaccines, therapeutics, and diagnostics. Biomedical innovation ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果